McKesson Corporation vs Global X Defense Tech ETF — how do they compare? McKesson Corporation trades at $832.45 (market cap $97.35B), while Global X Defense Tech ETF trades at $60.14. The key difference: McKesson Corporation pays a 0.39% dividend while Global X Defense Tech ETF pays none, and McKesson Corporation is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals.
| MCK | SHLD | |
|---|---|---|
Market Cap | $97.35B | — |
Sector | Health | Sector/Thematic |
52-Week High | $995.69 | $78.02 |
52-Week Low | $659.01 | $58.20 |
Enterprise Value | $101.98B | — |
Dividend Yield | 0.39% | — |
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $828.84, down 1.49% on the day, with a bullish technical outlook supported by moving averages and key support at $826. The company shows strong revenue growth, reaching $359.05B in 2025, and has beaten EPS estimates for three consecutive quarters. Analyst sentiment is overwhelmingly positive with 24 buy ratings and a consensus price target of $932.83, indicating 12.5% upside potential.
The outlook for MCK remains favorable due to consistent earnings beats, robust cash flow generation, and leadership in healthcare distribution. Risks include thin profit margins (1.18% net margin) and high liabilities relative to equity. Investors should focus on execution in specialty pharma and oncology services as key growth drivers amid competitive and regulatory pressures.
SHLD trades at $60.03, down slightly by 0.05% with a bearish technical signal from moving averages. The ETF offers exposure to global defense technology companies amid rising military spending trends. Recent news highlights institutional buying interest and geopolitical tailwinds supporting the sector's growth outlook.
The defense technology theme benefits from increased global budgets, but SHLD faces competition from other defense ETFs and valuation concerns. Near-term technical support at $59 could stabilize declines, while resistance at $61 may cap upside. Risks include political shifts and execution challenges among holdings.
Trailing returns across standard periods
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →